Loading...
NPI 1679662688 · Henderson, NV · Medical Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Ghulam Kashef is a medical oncology physician provider located in Henderson, Nevada. This profile covers 75 Medicare and 4 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Ghulam Kashef |
| Address | 10001 S Eastern Ave Ste 108 |
| City | Henderson |
| State | NV |
| ZIP | 89052 |
| Taxonomy | Medical Oncology Physician |
| NPI Enumerated | October 11, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.1M |
| Medicaid | $17.1K |
This provider’s business is heavily Medicare-facing: lifetime Medicare revenue is $2.1M compared with just $17.1K in Medicaid, so Medicare dominates the payment mix and Medicaid represents only a very small share of reported revenue. The provider should be considered effectively Medicare-centric based on scale alone.
Revenue concentration on Medicare is high and driven by a few drug codes: the precomputed top-3 Medicare codes account for 75.1% of this provider’s Medicare revenue, led by J9271 (50.3% of Medicare revenue), followed by J9144 (18.1%) and J0897 (6.7%). This concentration indicates most Medicare dollars flow through a small set of high-cost injectable therapies.
The CPT/HCPCS mix and top drug codes point to an infusion-centered oncology practice: large volumes of J9271 (pembrolizumab), J9144 (daratumumab), plus chemotherapy administration codes like 96413 and infusion add-on codes (96417, 96415) indicate in-office/infusion-suite delivery of monoclonal antibodies and cytotoxic/biologic oncology therapies. Frequent lab codes (85025, 80053) and phlebotomy (36415) support a model of ongoing therapy monitoring and infusion visits.
Competitive standing for Medicare is mixed by code: J9271 appears above-average nationally (rank #251 of 1841, 86th percentile; labeled typical, unremarkable volume), and J9144 is a modest national participant (rank #224 of 615, 63th percentile; labeled typical, unremarkable volume), so the provider has solid but not dominant national presence for those top drugs. In contrast, office E/M code 99214 ranks #25448 of 479517 (95th percentile) and is explicitly labeled notably above typical national volume, signaling stronger-than-average E/M activity relative to national peers.
Medicaid activity is narrowly focused and nearly entirely office-visits: the precomputed top-3 Medicaid codes account for 99.2% of Medicaid revenue, made up of 99214 (58.2%), 99213 (28.1%) and 99204 (12.8%). Those three visit codes imply the provider’s Medicaid revenue derives almost exclusively from evaluation-and-management encounters rather than drug administration.
The provider’s absolute claim counts for leading Medicare drug codes are substantial: J9271 shows 23.8K claims and J9144 shows 9.7K claims, which aligns with a high-throughput infusion practice or participation in a clinic that administers frequent immunotherapy and monoclonal antibody doses. These volumes, paired with the revenue concentration, suggest operational emphasis on recurring in-office biologic therapy delivery.
Several ancillary procedure-level signals reinforce an infusion/therapy monitoring workflow: high-ranked lab and phlebotomy codes (85025 at 96th percentile labeled typical, unremarkable; 36415 at 98th percentile labeled typical, unremarkable) and frequent infusion-related administration codes (96413, 96365, 96375) indicate routine lab monitoring and multiple infusion encounters per patient. Together these patterns are consistent with longitudinal oncology care requiring repeated labs and medication administration.
This NPI has long tenure in the market: the provider enumerated on 2006-10-11 (~20 years ago), indicating an established presence that could support ongoing referral relationships and sustained treatment volumes in the local oncology market.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
75 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 23,800 | $40 | $1M |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase‑fihj | 9,720 | $40 | $369.4K |
| J0897 | Injection, denosumab, 1 mg | 7,560 | $20 | $136.1K |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 3,610 | $30 | $122.7K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 710 | $90 | $65.3K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 30,050 | $1 | $60.1K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 440 | $100 | $44.6K |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,920 | $20 | $42.2K |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 300 | $100 | $30K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 360 | $70 | $23.3K |
Showing 1–10 of 75
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 75 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
75 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 4 | 40 | 13,000 | $40 | $625.8K |
| J9144 | 5 | 10 | 9,180 | $40 | $445.4K |
| J1568 | 9 | 10 | 4,470 | $30 | $164.2K |
| J0897 | 12 | 70 | 3,630 | $20 | $94.6K |
| J0881 | 10 | 30 | 17,400 | $1 | $49.5K |
| Q5119 | 4 | 10 | 2,050 | $20 | $46.4K |
| 82306 | 17 | 30 | 80 | $30 | $41.9K |
| Q5122 | 6 | 10 | 350 | $90 | $37.7K |
| J9217 | 19 | 40 | 120 | $130 | $23.9K |
| 96413 | 8 | 70 | 210 | $100 | $23.7K |
Showing 1–10 of 75
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 110 | $90 | $10K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 70 | $70 | $4.8K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 20 | $150 | $2.2K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 20 | $10 | $140 |
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
4 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,551 | 2,250 | 290 | $60 | $138K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,914 | 2,480 | 330 | $50 | $107.6K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 678 | 780 | 90 | $100 | $46.6K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 149 | 160 | 1,190 | $1 | $39.8K |
Other providers in the same ZIP code as Ghulam Kashef, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.